Published in Healthcare Mergers, Acquisitions and Ventures Week, December 23rd, 2006
The alliance fortifies companies' efforts in research, development and commercialization of novel anticancer therapeutics. Proteologics and Teva partner in two independent, yet complementary projects, focusing on specific components of the ubiquitin system. Successful identification and validation of a novel target triggered entrance into the second phase of the collaboration moving ahead into drug discovery. This progress follows the accomplishments of another joint Proteologics and Teva project, whereby small molecules are expected to enter animal tests later next...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week